Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555383 | 0.82 | TLR8 (0.37) | TLR8LRRK2CDK2KDRLMNA | |
| SCHEMBL24087394 | 0.77 | SDHB (0.39) | TLR8LRRK2CDK2KDRNR1H2 | |
| SCHEMBL29141591 | 0.74 | TLR9 (0.39) | TLR8LRRK2CDK2KDRNR1H2 | |
| SCHEMBL20555638 | 0.72 | LRRK2 (0.44) | LRRK2XPO1 | |
| SCHEMBL25243394 | 0.72 | KDR (0.44) | LRRK2CDK2KDRNR1H2NR1H3 | |
| SCHEMBL31726565 | 0.72 | KDR (0.44) | LRRK2CDK2KDRNR1H2NR1H3 | |
| SCHEMBL20555399 | 0.72 | SMN1; SMN2 (0.33) | TLR8LRRK2CDK2KDRLMNA | |
| SCHEMBL29820783 | 0.72 | CCNE1 (0.44) | CDK2LMNAPTK2CCNE1 | |
| SCHEMBL12795953 | 0.70 | PDE4B (0.44) | TP53L3MBTL1 | |
| SCHEMBL30703638 | 0.70 | JAK3 (0.46) | TLR8LRRK2CDK2KDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | TLR8 4382/4885LRRK2 1/4885CDK2 51/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | TLR8 4379/4885LRRK2 1/4885CDK2 51/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | TLR8 4382/4885LRRK2 1/4885CDK2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.